Why the study?
Do non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) slow eGFR decline and reduce proteinuria in patients with non-diabetic kidney disease?
Population
Patients with non-diabetic kidney disease, specifically proteinuric chronic kidney disease without diabetes
Design
Review
Key result
Finerenone significantly slowed kidney function decline compared to placebo in adults with non-diabetic chronic kidney disease, with a between-group difference in eGFR slope of 0.7 mL/min/1.73 m² per year.
Authors
Loading...
May support ns-MRA consideration in selected non-diabetic proteinuric CKD; leaves open dedicated RCTs for specific glomerulopathies.
Do non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) slow eGFR decline and reduce proteinuria in patients with non-diabetic kidney disease?
Mean Difference: 0.7
Absolute Event Rate: -3.3% vs -4%
p-value: p=<0.001
Non-steroidal MRAs such as finerenone demonstrate multi-level protective effects and slow eGFR decline in non-diabetic proteinuric kidney disease, expanding their therapeutic role.
Luo et al. (2026) conducted a review in Non-diabetic chronic kidney disease (n=1,584). Finerenone vs. Placebo was evaluated on Total eGFR slope (mean annual rate of change in eGFR from baseline to month 32) (MD 0.7, p=<0.001). Finerenone significantly slowed kidney function decline compared to placebo in adults with non-diabetic chronic kidney disease, with a between-group difference in eGFR slope of 0.7 mL/min/1.73 m² per year.